Asabys, a CataloniaBio & HealthTech member, has announced the launch of a new fund, Sabadell Asabys Health Innovation Investments II (SAHII 2), to continue investing in health innovation technologies and consolidate its presence as leading venture capital firm in the space in Southern Europe.
The fund’s first closing is expected by the end of this year, with commitments from institutional and private investors such as Banc Sabadell and the Alantra Investment Pool (Alantra & Mutua). SAHII 2 will invest in digital health, medtech and biotech companies, developing disruptive solutions with solid scientific evidence to improve patient outcomes.
Asabys was founded by Josep Ll. Sanfeliu and Clara Campàs in 2018 with the support of Alantra as strategic partner. Banc Sabadell, who was the anchor investor of the firm’s first fund, will also be the main investor in this new vehicle. With close to 120 million euros in AUM, Asabys has invested in 13 companies (1 exited) in the biopharma, medtech and digital health sectors
Josep Ll. Sanfeliu comments “Asabys was born with the mission to invest health innovation across the board and the reality is that the space has been converging technologically, creating countless opportunities to solve the challenges that medicine has nowadays by integrating biology or pharmacy with nanotechnologies, digitalization or artificial intelligence.”
Clara Campàs adds “With this second fund we will continue investing in the creation of new companies, as well as consolidate existing ones, with the goal to transform disruptive science in real solutions for patients.”
Photo: Josep Ll. Sanfeliu and Clara Campàs
Comments